Finastéride oral 1 mg face à Dutastéride oral 0,5 mg

Table 2: Blinded investigator’s assessment of hair growth on global photograph between dutasteride and fi nasteride cases Blinded investigator’s Drug n (%) Total, assessment of global n (%) Dutasteride Finasteride photograph Slightly decreased 0 (0) 5 (13.5) 5 (6.9) No change 3 (8.6) 12 (32.4) 15 (20.8) Slightly increased 6 (17.1) 8 (21.6) 14 (19.4) Moderately increased 13 (37.1) 10 (27) 23 (31.9) Greatly increased 13 (37.1) 2 (5.4) 15 (20.8) Total 35 (100) 37 (100) 72 (100) P=0.00075

Shanshanwal SJ, Dhurat RS. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study. Indian Journal of Dermatology, Venereology and Leprology 2017, DOI 10.4103/0378-6323.188652. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Table 2: Blinded investigator’s assessment of hair growth on global photograph between dutasteride and fi nasteride cases Blinded investigator’s Drug n (%) Total, assessment of global n (%) Dutasteride Finasteride photograph Slightly decreased 0 (0) 5 (13.5) 5 (6.9) No change 3 (8.6) 12 (32.4) 15 (20.8) Slightly increased 6 (17.1) 8 (21.6) 14 (19.4) Moderately increased 13 (37.1) 10 (27) 23 (31.9) Greatly increased 13 (37.1) 2 (5.4) 15 (20.8) Total 35 (100) 37 (100) 72 (100) P=0.00075

Shanshanwal SJ, Dhurat RS. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study. Indian Journal of Dermatology, Venereology and Leprology 2017, DOI 10.4103/0378-6323.188652. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Dutasteride (n=35) Finasteride (n=37) P Mean SD Mean SD 222.83 50.68 226.78 48.80 0.485 245.97 49.86 231.08 51.08 0.215 23.14 8.44 4.30 12.46 <0.001* 11 5 2 5 <0.001* 64.57 26.89 67.32 29.87 0.628 57.20 24.77 66.05 25.04 0.098 7.37 11.99 1.27 15.03 0.0156* 10 18 0 18 0.0209* 158.26 49.91 159.46 42.27 0.912 188.77 46.49 165.03 44.38 0.02985* 30.51 12.86 5.57 12.97 <0.001* 24 22 4 8 <0.001* 2.23 0.81 0.95 1.18 <0.001* 2.03 0.95 0.78 1.16 <0.001* 2.83 1.01 2.00 0.94 <0.001*

Citation complémentaire (methode)

Table 1: The baseline characteristics of patients in two groups Variables Total hair count - baseline Total hair count - 24 weeks Total hair count - change in number Total hair count - percentage change Thin hair count - baseline Thin hair count - 24 weeks Thin hair count - change in number Thin hair count - percentage change in number Thick hair count - baseline Thick hair count - 24 weeks Thick hair count - change in number Thick hair count - percentage change in number Non-blinded investigator’s assessment of global photographs Blinded investigator’s assessment of global photographs Overall satisfaction on subjective evaluation *Signifi cant P<0.05. n: Number, SD: Standard deviation

Shanshanwal SJ, Dhurat RS. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study. Indian Journal of Dermatology, Venereology and Leprology 2017, DOI 10.4103/0378-6323.188652. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Dutasteride (n=35) Finasteride (n=37) P Mean SD Mean SD 222.83 50.68 226.78 48.80 0.485 245.97 49.86 231.08 51.08 0.215 23.14 8.44 4.30 12.46 <0.001* 11 5 2 5 <0.001* 64.57 26.89 67.32 29.87 0.628 57.20 24.77 66.05 25.04 0.098 7.37 11.99 1.27 15.03 0.0156* 10 18 0 18 0.0209* 158.26 49.91 159.46 42.27 0.912 188.77 46.49 165.03 44.38 0.02985* 30.51 12.86 5.57 12.97 <0.001* 24 22 4 8 <0.001* 2.23 0.81 0.95 1.18 <0.001* 2.03 0.95 0.78 1.16 <0.001* 2.83 1.01 2.00 0.94 <0.001*

Citation complémentaire (methode)

Table 1: The baseline characteristics of patients in two groups Variables Total hair count - baseline Total hair count - 24 weeks Total hair count - change in number Total hair count - percentage change Thin hair count - baseline Thin hair count - 24 weeks Thin hair count - change in number Thin hair count - percentage change in number Thick hair count - baseline Thick hair count - 24 weeks Thick hair count - change in number Thick hair count - percentage change in number Non-blinded investigator’s assessment of global photographs Blinded investigator’s assessment of global photographs Overall satisfaction on subjective evaluation *Signifi cant P<0.05. n: Number, SD: Standard deviation

Shanshanwal SJ, Dhurat RS. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study. Indian Journal of Dermatology, Venereology and Leprology 2017, DOI 10.4103/0378-6323.188652. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Dutasteride (n=35) Finasteride (n=37) P Mean SD Mean SD 222.83 50.68 226.78 48.80 0.485 245.97 49.86 231.08 51.08 0.215 23.14 8.44 4.30 12.46 <0.001* 11 5 2 5 <0.001* 64.57 26.89 67.32 29.87 0.628 57.20 24.77 66.05 25.04 0.098 7.37 11.99 1.27 15.03 0.0156* 10 18 0 18 0.0209* 158.26 49.91 159.46 42.27 0.912 188.77 46.49 165.03 44.38 0.02985* 30.51 12.86 5.57 12.97 <0.001*

Citation complémentaire (methode)

Table 1: The baseline characteristics of patients in two groups Variables Total hair count - baseline Total hair count - 24 weeks Total hair count - change in number Total hair count - percentage change Thin hair count - baseline Thin hair count - 24 weeks Thin hair count - change in number Thin hair count - percentage change in number Thick hair count - baseline Thick hair count - 24 weeks Thick hair count - change in number Thick hair count - percentage change in number Non-blinded investigator’s assessment of global photographs Blinded investigator’s assessment of global photographs Overall satisfaction on subjective evaluation *Signifi cant P<0.05. n: Number, SD: Standard deviation

Shanshanwal SJ, Dhurat RS. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study. Indian Journal of Dermatology, Venereology and Leprology 2017, DOI 10.4103/0378-6323.188652. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Dutasteride (n=35) Finasteride (n=37) P Mean SD Mean SD 222.83 50.68 226.78 48.80 0.485 245.97 49.86 231.08 51.08 0.215 23.14 8.44 4.30 12.46 <0.001* 11 5 2 5 <0.001* 64.57 26.89 67.32 29.87 0.628 57.20 24.77 66.05 25.04 0.098 7.37 11.99 1.27 15.03 0.0156* 10 18 0 18 0.0209* 158.26 49.91 159.46 42.27 0.912 188.77 46.49 165.03 44.38 0.02985* 30.51 12.86 5.57 12.97 <0.001*

Citation complémentaire (methode)

Table 1: The baseline characteristics of patients in two groups Variables Total hair count - baseline Total hair count - 24 weeks Total hair count - change in number Total hair count - percentage change Thin hair count - baseline Thin hair count - 24 weeks Thin hair count - change in number Thin hair count - percentage change in number Thick hair count - baseline Thick hair count - 24 weeks Thick hair count - change in number Thick hair count - percentage change in number Non-blinded investigator’s assessment of global photographs Blinded investigator’s assessment of global photographs Overall satisfaction on subjective evaluation *Signifi cant P<0.05. n: Number, SD: Standard deviation

Shanshanwal SJ, Dhurat RS. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study. Indian Journal of Dermatology, Venereology and Leprology 2017, DOI 10.4103/0378-6323.188652. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

The mean change in total hair count after 24 weeks of treatment was significantly greater in the dutasteride group (23.14/cm2) compared with the finasteride group (4.3/cm2)

Citation complémentaire (inclusion)

Dutasteride (n=35) Finasteride (n=37) P Mean SD Mean SD 222.83 50.68 226.78 48.80 0.485

Citation complémentaire (significativite)

23.14 8.44 4.30 12.46 <0.001*

Shanshanwal SJ, Dhurat RS. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study. Indian Journal of Dermatology, Venereology and Leprology 2017, DOI 10.4103/0378-6323.188652. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

The mean change in total hair count after 24 weeks of treatment was significantly greater in the dutasteride group (23.14/cm2) compared with the finasteride group (4.3/cm2)

Citation complémentaire (inclusion)

Dutasteride (n=35) Finasteride (n=37) P Mean SD Mean SD 222.83 50.68 226.78 48.80 0.485

Citation complémentaire (significativite)

23.14 8.44 4.30 12.46 <0.001*

Shanshanwal SJ, Dhurat RS. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study. Indian Journal of Dermatology, Venereology and Leprology 2017, DOI 10.4103/0378-6323.188652. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Thin hair counts decreased significantly (7.37/cm2) in the dutasteride group at 24 weeks as compared to the finasteride group (1.27/cm2, P = 0.0156)

Citation complémentaire (inclusion)

Dutasteride (n=35) Finasteride (n=37) P Mean SD Mean SD 222.83 50.68 226.78 48.80 0.485 245.97 49.86 231.08 51.08 0.215 23.14 8.44 4.30 12.46 <0.001* 11 5 2 5 <0.001* 64.57 26.89 67.32 29.87 0.628

Shanshanwal SJ, Dhurat RS. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study. Indian Journal of Dermatology, Venereology and Leprology 2017, DOI 10.4103/0378-6323.188652. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Thin hair counts decreased significantly (7.37/cm2) in the dutasteride group at 24 weeks as compared to the finasteride group (1.27/cm2, P = 0.0156)

Citation complémentaire (inclusion)

Dutasteride (n=35) Finasteride (n=37) P Mean SD Mean SD 222.83 50.68 226.78 48.80 0.485 245.97 49.86 231.08 51.08 0.215 23.14 8.44 4.30 12.46 <0.001* 11 5 2 5 <0.001* 64.57 26.89 67.32 29.87 0.628

Shanshanwal SJ, Dhurat RS. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study. Indian Journal of Dermatology, Venereology and Leprology 2017, DOI 10.4103/0378-6323.188652. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Most adverse events reported post-randomization were mild to moderate (dutasteride group, n = 8; finasteride group, n = 7)

Shanshanwal SJ, Dhurat RS. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study. Indian Journal of Dermatology, Venereology and Leprology 2017, DOI 10.4103/0378-6323.188652. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Most adverse events reported post-randomization were mild to moderate (dutasteride group, n = 8; finasteride group, n = 7)

Shanshanwal SJ, Dhurat RS. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study. Indian Journal of Dermatology, Venereology and Leprology 2017, DOI 10.4103/0378-6323.188652. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

to 1 and 3 patients in finasteride group, respectively but this was not statistically significant.

Citation complémentaire (population)

Erectile dysfunction and loss of libido was seen in 3 and 4 patients in the dutasteride group as compared

Shanshanwal SJ, Dhurat RS. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study. Indian Journal of Dermatology, Venereology and Leprology 2017, DOI 10.4103/0378-6323.188652. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Erectile dysfunction and loss of libido was seen in 3 and 4 patients in the dutasteride group as compared

Shanshanwal SJ, Dhurat RS. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study. Indian Journal of Dermatology, Venereology and Leprology 2017, DOI 10.4103/0378-6323.188652. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

to 1 and 3 patients in finasteride group, respectively but this was not statistically significant.

Citation complémentaire (population)

Erectile dysfunction and loss of libido was seen in 3 and 4 patients in the dutasteride group as compared

Shanshanwal SJ, Dhurat RS. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study. Indian Journal of Dermatology, Venereology and Leprology 2017, DOI 10.4103/0378-6323.188652. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Erectile dysfunction and loss of libido was seen in 3 and 4 patients in the dutasteride group as compared

Shanshanwal SJ, Dhurat RS. Superiority of dutasteride over finasteride in hair regrowth and reversal of miniaturization in men with androgenetic alopecia: A randomized controlled open-label, evaluator-blinded study. Indian Journal of Dermatology, Venereology and Leprology 2017, DOI 10.4103/0378-6323.188652. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Adjusted meanHGItotalscoresatweek24were significantly higher in the dutasteride 0.1 mg (2.8), dutasteride0.5mg(3.2),andfinasteride(2.5)groups versus placebo (1.1; all P \ .001); there was no significant difference between adjusted mean HGI total scores in the dutasteride 0.02 mg (1.1) and placebo(1.1;P=.80)groups.

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Adjusted meanHGItotalscoresatweek24were significantly higher in the dutasteride 0.1 mg (2.8), dutasteride0.5mg(3.2),andfinasteride(2.5)groups versus placebo (1.1; all P \ .001); there was no significant difference between adjusted mean HGI total scores in the dutasteride 0.02 mg (1.1) and placebo(1.1;P=.80)groups.

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Hair count (2.54-cm diameter). The increase inbaselinehaircountwassuperiorinthedutasteride 0.1,dutasteride0.5mg,andfinasteridegroupsversus placebo at week 24 (all P \ .001) (Fig 2, A).

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Hair count (2.54-cm diameter). The increase inbaselinehaircountwassuperiorinthedutasteride 0.1,dutasteride0.5mg,andfinasteridegroupsversus placebo at week 24 (all P \ .001) (Fig 2, A). Dutasteride 0.1 and 0.5 mg were noninferior to

Citation complémentaire (significativite)

finasteride at week 24 (1-sided 99.165% confidence interval:(cid:1)20.1to33.1and6.1to60.0,respectively); however, only dutasteride 0.5 mg was superior to finasterideatweeks12and24(bothP=.003).

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Terminal hair count. Adjusted mean change from baseline in terminal hair count (2.54-cm 6 Gubelin Harcha et al Fig 3. Adjusted mean change from baseline in JAMACADDERMATOL target area (2.54-cm diameter) hair width ((cid:1)m31e-3)atweek24forplacebo,dutasteride0.02to0.5mg,andfinasteride1mg.*P\.001 vsplacebo;yP=.004vsfinasteride(superiority). Fig4. Medianscoresforpanelglobalphotographicassessmentofimprovementofhairgrowth at the vertex and frontal/superior views at week 24. *P \.001 vs placebo; yP = .002 vs finasteride(superiority). diameter) at week 24 was superior in the dutaster- ide 0.1 and 0.5 mg (29.4 and 46.0 hairs) and finasteride (36.3 hairs) groups versus placebo ((cid:1)17.5 hairs; all P \ .001); dutasteride 0.02 mg was not superior to placebo ((cid:1)15.7 hairs, P = .81). Dutasteride 0.1 and 0.5 mg were not superior to finasterideatincreasingterminalhaircountatweek 24 (P = .34 and P = .19).

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Terminal hair count. Adjusted mean change from baseline in terminal hair count (2.54-cm 6 Gubelin Harcha et al Fig 3. Adjusted mean change from baseline in JAMACADDERMATOL target area (2.54-cm diameter) hair width ((cid:1)m31e-3)atweek24forplacebo,dutasteride0.02to0.5mg,andfinasteride1mg.*P\.001 vsplacebo;yP=.004vsfinasteride(superiority). Fig4. Medianscoresforpanelglobalphotographicassessmentofimprovementofhairgrowth at the vertex and frontal/superior views at week 24. *P \.001 vs placebo; yP = .002 vs finasteride(superiority). diameter) at week 24 was superior in the dutaster- ide 0.1 and 0.5 mg (29.4 and 46.0 hairs) and finasteride (36.3 hairs) groups versus placebo ((cid:1)17.5 hairs; all P \ .001); dutasteride 0.02 mg was not superior to placebo ((cid:1)15.7 hairs, P = .81). Dutasteride 0.1 and 0.5 mg were not superior to finasterideatincreasingterminalhaircountatweek 24 (P = .34 and P = .19).

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Hair count (1.13-cm diameter). All active treatment groups except dutasteride 0.02 mg were superiortoplaceboinincreasinghaircountatweek 24 (all P \ .001) (Fig 2, B). Dutasteride 0.5 mg JAMACADDERMATOL Gubelin Harcha etal 5 Fig2. A,Adjustedmeanchangefrombaselineintargetareahaircount(2.54cm)atweeks12and24 forplacebo,dutasteride 0.02 to 0.5mg,and finasteride 1mg.*P= .009,yP\.001 vsplacebo; znoninferiortofinasteride;xP=.003vsfinasteride(superiority).B,Adjustedmeanchangefrom baselineintargetareahaircount(1.13cm)atweeks12and24forplacebo,dutasteride0.02to0.5mg, andfinasteride1mg.*P=.015,yP\.001vsplacebo;xP=.008,**P=.016vsfinasteride(superiority). significantly increased hair count versus finasteride atweek24(P=.016).

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Hair count (1.13-cm diameter). All active treatment groups except dutasteride 0.02 mg were superiortoplaceboinincreasinghaircountatweek 24 (all P \ .001) (Fig 2, B). Dutasteride 0.5 mg JAMACADDERMATOL Gubelin Harcha etal 5 Fig2. A,Adjustedmeanchangefrombaselineintargetareahaircount(2.54cm)atweeks12and24 forplacebo,dutasteride 0.02 to 0.5mg,and finasteride 1mg.*P= .009,yP\.001 vsplacebo; znoninferiortofinasteride;xP=.003vsfinasteride(superiority).B,Adjustedmeanchangefrom baselineintargetareahaircount(1.13cm)atweeks12and24forplacebo,dutasteride0.02to0.5mg, andfinasteride1mg.*P=.015,yP\.001vsplacebo;xP=.008,**P=.016vsfinasteride(superiority). significantly increased hair count versus finasteride atweek24(P=.016).

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Hair width. Dutasteride0.1,dutasteride0.5mg, and finasteride were superior to placebo at increasing hair width (2.54-cm diameter) versus placebo at week 24 (all P \ .001) (Fig 3); only dutasteride0.5mgsignificantlyincreasedhairwidth versusfinasterideatweek24(P=.004).

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Hair width. Dutasteride0.1,dutasteride0.5mg, and finasteride were superior to placebo at increasing hair width (2.54-cm diameter) versus placebo at week 24 (all P \ .001) (Fig 3); only dutasteride0.5mgsignificantlyincreasedhairwidth versusfinasterideatweek24(P=.004).

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Investigator assessment IPAQ scores at week 24 are shown in Table III (available at http://www.jaad.org). Compared with placebo, dutasteride 0.1, dutasteride 0.5 mg, and finasteride significantly improved hair growth (assessed by adjusted mean IPAQ scores) in the vertex(1.03,1.30,and1.07vs0.36,respectively)and frontal/superior views (0.78, 1.11, and 0.88 vs 0.30, respectively) at week 24 (all P\.001). Dutasteride was not superior to finasteride at improving hair growth in the vertex and frontal/superior views (assessedbymeanIPAQscores)atweek24.

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Investigator assessment IPAQ scores at week 24 are shown in Table III (available at http://www.jaad.org). Compared with placebo, dutasteride 0.1, dutasteride 0.5 mg, and finasteride significantly improved hair growth (assessed by adjusted mean IPAQ scores) in the vertex(1.03,1.30,and1.07vs0.36,respectively)and frontal/superior views (0.78, 1.11, and 0.88 vs 0.30, respectively) at week 24 (all P\.001). Dutasteride was not superior to finasteride at improving hair growth in the vertex and frontal/superior views (assessedbymeanIPAQscores)atweek24.

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Investigator assessment IPAQ scores at week 24 are shown in Table III (available at http://www.jaad.org). Compared with placebo, dutasteride 0.1, dutasteride 0.5 mg, and finasteride significantly improved hair growth (assessed by adjusted mean IPAQ scores) in the vertex(1.03,1.30,and1.07vs0.36,respectively)and frontal/superior views (0.78, 1.11, and 0.88 vs 0.30, respectively) at week 24 (all P\.001). Dutasteride was not superior to finasteride at improving hair growth in the vertex and frontal/superior views (assessedbymeanIPAQscores)atweek24.

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

Investigator assessment IPAQ scores at week 24 are shown in Table III (available at http://www.jaad.org). Compared with placebo, dutasteride 0.1, dutasteride 0.5 mg, and finasteride significantly improved hair growth (assessed by adjusted mean IPAQ scores) in the vertex(1.03,1.30,and1.07vs0.36,respectively)and frontal/superior views (0.78, 1.11, and 0.88 vs 0.30, respectively) at week 24 (all P\.001). Dutasteride was not superior to finasteride at improving hair growth in the vertex and frontal/superior views (assessedbymeanIPAQscores)atweek24.

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableV.Adverseevents,includingcommonadverseeventsreportedpostrandomizationbytreatmentgroup Placebo N=181 Dutasteride Finasteride 0.02mg 0.1mg 0.5mg 1mg N=185 N=188 N=184 N=179 n(%)[events] n(%)[events] n(%)[events] n(%)[events] n(%)[events] AnyAE 94(52)[185] 91 Anydrug-related AE 27(15)[40] 26

Citation complémentaire (valeur)

(49)[192] 95(51)[201] 100 (54)[217] 94(53)[189] (14)[48] 39(21)[52] 30(16)[41] 35(20)[48]

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableV.Adverseevents,includingcommonadverseeventsreportedpostrandomizationbytreatmentgroup Placebo N=181 Dutasteride Finasteride 0.02mg 0.1mg 0.5mg 1mg N=185 N=188 N=184 N=179 n(%)[events] n(%)[events] n(%)[events] n(%)[events] n(%)[events] AnyAE 94(52)[185] 91 Anydrug-related AE 27(15)[40] 26

Citation complémentaire (valeur)

(49)[192] 95(51)[201] 100 (54)[217] 94(53)[189] (14)[48] 39(21)[52] 30(16)[41] 35(20)[48]

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableV.Adverseevents,includingcommonadverseeventsreportedpostrandomizationbytreatmentgroup Placebo N=181 Dutasteride Finasteride 0.02mg 0.1mg 0.5mg 1mg N=185 N=188 N=184 N=179 n(%)[events] n(%)[events] n(%)[events] n(%)[events] n(%)[events] AnyAE 94(52)[185] 91 Anydrug-related AE 27(15)[40] 26

Citation complémentaire (valeur)

(49)[192] 95(51)[201] 100 (54)[217] 94(53)[189] (14)[48] 39(21)[52] 30(16)[41] 35(20)[48]

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableV.Adverseevents,includingcommonadverseeventsreportedpostrandomizationbytreatmentgroup Placebo N=181 Dutasteride Finasteride 0.02mg 0.1mg 0.5mg 1mg N=185 N=188 N=184 N=179 n(%)[events] n(%)[events] n(%)[events] n(%)[events] n(%)[events] AnyAE 94(52)[185] 91 Anydrug-related AE 27(15)[40] 26

Citation complémentaire (valeur)

(49)[192] 95(51)[201] 100 (54)[217] 94(53)[189] (14)[48] 39(21)[52] 30(16)[41] 35(20)[48]

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableV.Adverseevents,includingcommonadverseeventsreportedpostrandomizationbytreatmentgroup Placebo N=181 Dutasteride Finasteride 0.02mg 0.1mg 0.5mg 1mg N=185 N=188 N=184 N=179 n(%)[events] n(%)[events] n(%)[events] n(%)[events] n(%)[events] AnyAE 94(52)[185] 91 Anydrug-related AE 27(15)[40] 26 AnySAE* 2(1) [2] Death 0 CommonAEs ($3% inany group) Nasopharyngitis 16(9) 19 Decreased libido 2(1) 10

Citation complémentaire (valeur)

(49)[192] 95(51)[201] 100 (54)[217] 94(53)[189] (14)[48] 39(21)[52] 30(16)[41] 35(20)[48] 0 3 (2)[4] 1 (\1)[3] 2 (1)[4] 0 0 0 0 (10) 15(8) 23(13) 14(8) (5) 9 (5) 6 (3) 9 (5)

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableV.Adverseevents,includingcommonadverseeventsreportedpostrandomizationbytreatmentgroup Placebo N=181 Dutasteride Finasteride 0.02mg 0.1mg 0.5mg 1mg N=185 N=188 N=184 N=179 n(%)[events] n(%)[events] n(%)[events] n(%)[events] n(%)[events] AnyAE 94(52)[185] 91 Anydrug-related AE 27(15)[40] 26 AnySAE* 2(1) [2] Death 0 CommonAEs ($3% inany group) Nasopharyngitis 16(9) 19 Decreased libido 2(1) 10

Citation complémentaire (valeur)

(49)[192] 95(51)[201] 100 (54)[217] 94(53)[189] (14)[48] 39(21)[52] 30(16)[41] 35(20)[48] 0 3 (2)[4] 1 (\1)[3] 2 (1)[4] 0 0 0 0 (10) 15(8) 23(13) 14(8) (5) 9 (5) 6 (3) 9 (5)

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableV.Adverseevents,includingcommonadverseeventsreportedpostrandomizationbytreatmentgroup Placebo N=181 Dutasteride Finasteride 0.02mg 0.1mg 0.5mg 1mg N=185 N=188 N=184 N=179 n(%)[events] n(%)[events] n(%)[events] n(%)[events] n(%)[events] AnyAE 94(52)[185] 91 Anydrug-related AE 27(15)[40] 26 AnySAE* 2(1) [2] Death 0 CommonAEs ($3% inany group) Nasopharyngitis 16(9) 19 Decreased libido 2(1) 10 Headache 16(9) 8 Erectiledysfunction 7(4) 8

Citation complémentaire (valeur)

(49)[192] 95(51)[201] 100 (54)[217] 94(53)[189] (14)[48] 39(21)[52] 30(16)[41] 35(20)[48] 0 3 (2)[4] 1 (\1)[3] 2 (1)[4] 0 0 0 0 (10) 15(8) 23(13) 14(8) (5) 9 (5) 6 (3) 9 (5) (4) 8 (4) 11(6) 5 (3) (4) 7 (4) 10(5) 10(6)

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).

TableV.Adverseevents,includingcommonadverseeventsreportedpostrandomizationbytreatmentgroup Placebo N=181 Dutasteride Finasteride 0.02mg 0.1mg 0.5mg 1mg N=185 N=188 N=184 N=179 n(%)[events] n(%)[events] n(%)[events] n(%)[events] n(%)[events] AnyAE 94(52)[185] 91 Anydrug-related AE 27(15)[40] 26 AnySAE* 2(1) [2] Death 0 CommonAEs ($3% inany group) Nasopharyngitis 16(9) 19 Decreased libido 2(1) 10 Headache 16(9) 8 Erectiledysfunction 7(4) 8

Citation complémentaire (valeur)

(49)[192] 95(51)[201] 100 (54)[217] 94(53)[189] (14)[48] 39(21)[52] 30(16)[41] 35(20)[48] 0 3 (2)[4] 1 (\1)[3] 2 (1)[4] 0 0 0 0 (10) 15(8) 23(13) 14(8) (5) 9 (5) 6 (3) 9 (5) (4) 8 (4) 11(6) 5 (3) (4) 7 (4) 10(5) 10(6)

Gubelin Harcha W, Barboza Martínez J, Tsai TF et al.. A randomized, active- and placebo-controlled study of the efficacy and safety of different doses of dutasteride versus placebo and finasteride in the treatment of male subjects with androgenetic alopecia.. J Am Acad Dermatol 2014, DOI 10.1016/j.jaad.2013.10.049. Citation reproduite au titre du droit de courte citation (article L122-5 du Code de la propriété intellectuelle).